The lab was recently awarded a ~$2M R01 grant from NIH to tackle vaccine-associated hypoxia with advanced biomaterials to enhance cancer immunotherapy.
This project is focused on the development of biomaterial-based vaccines against prostate cancer. This work will integrate advanced injectable hydrogels, hypoxia-fighting nanoparticles, tumor-specific antigens, and immunostimulatory factors. We hypothesize that the proposed biomaterials can overcome hypoxia-driven immunosuppression in cancer vaccines and improve therapeutic efficacy.
The NIH fund will support this work in collaboration with Prof. Sitkovsky to further optimize and test this novel cancer vaccines in animal models, a critical step for translational research and moving on to the first stage of clinical testing in humans.
Check out the news story here for more information.
Posted: August 12, 2021 by bencheriflab
Prof. Bencherif receives NIH R01 Award
The lab was recently awarded a ~$2M R01 grant from NIH to tackle vaccine-associated hypoxia with advanced biomaterials to enhance cancer immunotherapy.
This project is focused on the development of biomaterial-based vaccines against prostate cancer. This work will integrate advanced injectable hydrogels, hypoxia-fighting nanoparticles, tumor-specific antigens, and immunostimulatory factors. We hypothesize that the proposed biomaterials can overcome hypoxia-driven immunosuppression in cancer vaccines and improve therapeutic efficacy.
The NIH fund will support this work in collaboration with Prof. Sitkovsky to further optimize and test this novel cancer vaccines in animal models, a critical step for translational research and moving on to the first stage of clinical testing in humans.
Check out the news story here for more information.
Category: Uncategorized